Investigational Site Number :6430004

Saint Petersburg 199106

0 studies enrolling now · 10 studies all time

What they study most

Asthma, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Heart Failure, Hypercholesterolaemia, Multiple Sclerosis, Non-relapsing Secondary Progressive Multiple Sclerosis, Relapsing Multiple Sclerosis, Type 2 Diabetes Mellitus

Studies at this site

• Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis — Running, not enrolling
• Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis — Completed
• Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) — Completed
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) — Completed
• Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation — Completed
• A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma — Completed
• Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk — Stopped early
• A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus — Completed
• An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia — Completed